Trial reportArchives of neurology2009
Urate as a predictor of the rate of clinical decline in Parkinson disease.
Trial report in Archives of neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
173 citing papers in PubMed, 4 syntheses or guidelines pooled it, 351 citations in OpenAlex.
- Risk of dementia or Parkinson's disease in the presence of Sjögren's syndrome: A systematic review and meta-analysis.Frontiers in integrative neuroscience · 2022Pooled it
- The significance of uric acid in the diagnosis and treatment of Parkinson disease: An updated systemic review.Medicine · 2017Pooled it
- Pooled it
- Serum uric acid level and association with cognitive impairment and dementia: systematic review and meta-analysis.Age (Dordrecht, Netherlands) · 2016Pooled it
- Trial
- Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine.Medicine · 2020Trial
- Plasma urate concentrations and possible REM sleep behavior disorder.Annals of clinical and translational neurology · 2019Trial
- Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial.Neurology · 2019Trial
- Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease.EBioMedicine · 2018Trial
- Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial.Movement disorders : official journal of the Movement Disorder Society · 2018Trial
- Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores.Neurology · 2017Trial
- Trial
- Serum urate at trial entry and ALS progression in EMPOWER.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2017Trial
- Mendelian randomization of serum urate and parkinson disease progression.Annals of neurology · 2014Trial
- Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.JAMA neurology · 2014Trial
- Routine Blood Indicators Combined With Sleep Questionnaires for the Identification of Cognitive Impairment in Parkinson's Disease: A Cross-Sectional Study With a Leakage-Free Nested Modeling Framework.Brain and behavior · 2026Article
- Sex- and Laterality-Specific Associations Between Serum Uric Acid-to-Creatinine Ratio and Gait Parameters in Parkinson's Disease.Brain and behavior · 2026Article
- New Active Biopolymers and Chitosan-Based Films from Non-Native Crayfish Shell.Molecules (Basel, Switzerland) · 2026Article
- Article
- Neuroinflammation and Oxidative Stress in Parkinson's Disease, Alzheimer's Disease, and COVID-19: Microglia-Neutrophil Interaction.ACS omega · 2026Review
113 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
20 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe risk of Parkinson disease (PD) and its rate of progression may decline with increasing concentration of blood urate, a major antioxidant.
objectiveTo determine whether serum and cerebrospinal fluid concentrations of urate predict clinical progression in patients with PD. DESIGN, SETTING, AND
participantsEight hundred subjects with early PD enrolled in the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial. The pretreatment urate concentration was measured in serum for 774 subjects and in cerebrospinal fluid for 713 subjects.
main outcome measuresTreatment-, age-, and sex-adjusted hazard ratios (HRs) for clinical disability requiring levodopa therapy, the prespecified primary end point of the original DATATOP trial.
resultsThe HR of progressing to the primary end point decreased with increasing serum urate concentrations (HR for highest vs lowest quintile = 0.64; 95% confidence interval [CI], 0.44-0.94; HR for a 1-SD increase = 0.82; 95% CI, 0.73-0.93). In analyses stratified by alpha-tocopherol treatment (2000 IU/d), a decrease in the HR for the primary end point was seen only among subjects not treated with alpha-tocopherol (HR for a 1-SD increase = 0.75; 95% CI, 0.62-0.89; vs HR for those treated = 0.90; 95% CI, 0.75-1.08). Results were similar for the rate of change in the Unified Parkinson's Disease Rating Scale score. Cerebrospinal fluid urate concentration was also inversely related to both the primary end point (HR for highest vs lowest quintile = 0.65; 95% CI, 0.44-0.96; HR for a 1-SD increase = 0.89; 95% CI, 0.79-1.02) and the rate of change in the Unified Parkinson's Disease Rating Scale score. As with serum urate concentration, these associations were present only among subjects not treated with alpha-tocopherol.
conclusionsHigher serum and cerebrospinal fluid urate concentrations at baseline were associated with slower rates of clinical decline. The findings strengthen the link between urate concentration and PD and the rationale for considering central nervous system urate concentration elevation as a potential strategy to slow PD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.